Stromedix

In February 2012 Biogen Idec (NASDAQ: BIIB) acquired Stromedix to develop the company’s novel pulmonary fibrosis therapeutic.

Headquarters	Cambridge, MA
Pipeline	Lead asset in Phase 2 studies at Biogen